Glyscend Inc

[Glyscend Inc @glyscend]

We’re celebrating a milestone: Glyscend was founded 10 years ago this week!

We are proud of the journey we’ve taken to turn an idea into a Phase 2 clinical-stage drug candidate, and we look forward to many more exciting years of progress ahead.

[Glyscend Inc @glyscend]

The Glyscend team will be in Orlando for the @AmericanDiabetesAssociation 84th Scientific Sessions where we look forward to engaging with the #diabetes and #obesity community.

[Glyscend Inc @glyscend]

Phase 2 clinical trial underway at five sites across the US! Study to assess weight-loss and evaluate safety and tolerability of GLY-200 after 16-weeks oral treatment in a non-diabetic obese population. Results expected 1Q2025.

#glyscend #obesity #t2diabetes #bio2024

[Glyscend Inc @glyscend]

Glyscend is honored to have been nominated by the Maryland Tech Council as a 2024 ICON Award finalist for Emerging Life Sciences Company of the Year. 

https://t.co/53a2wPdtzj
#t2d #biopharma #lifescience

[Glyscend Inc @glyscend]

The Glyscend team is looking forward to attending ObesityWeek 2023 hosted by The Obesity Society from October 14 to 17 in Dallas, TX! Join us as we present 3 abstracts highlighting our clinical and preclinical progress with our lead program for #obesity and #t2diabetes.

[Glyscend Inc @glyscend]

Our team welcomes Sapan Shah, PhD, as CEO. With 25+ years of experience leading innovative #lifescience companies, Dr. Shah is ready and well-equipped to guide Glyscend in its next stage of growth as it advances lead product candidate GLY-200 for #obesity and #type2diabetes.

[Glyscend Inc @glyscend]

Join us at the American Diabetes Association 83rd Scientific Sessions as we present 4 abstracts on our clinical and preclinical studies with GLY-200, an orally administered gut-targeted polymer therapy in development for the treatment of type 2 #diabetes and #obesity.

#ADA2023

[Glyscend Inc @glyscend]

We’re gearing up for #ADA2023 where we look forward to sharing more on our latest progress in the clinic with GLY-200 for the treatment of #T2D and #obesity!

In the meantime, learn more about our completed Phase 2a clinical study via Endpoints News.

https://t.co/KGJzpV1KcM

[Glyscend Inc @glyscend]

Check out this article from @biospace about our positive topline Phase 2a data for GLY-200, a first-in-class polymer drug, in people with Type 2 #Diabetes and #Obesity.

[BioSpace @biospace]

@glyscend Therapeutics’ lead candidate GLY-200 demonstrated promising safety and efficacy in patients with Type 2 diabetes.
#GlyscendTherapeutics #LifeSciences BioSpace
https://t.co/8ywpyjuLgB

[Glyscend Inc @glyscend]

https://t.co/MTcVeRPX0x.

[Glyscend Inc @glyscend]

We are excited to share positive topline results from our Phase 2a clinical trial. Data show the novel mechanism of GLY-200 offers significant reductions in postprandial glucose and body weight in people with type 2 #diabetes. Hear about our Ph 1 data at the 83rd @AmDiabetesAssn

[Glyscend Inc @glyscend]

Glyscend welcomes Michael Wyzga, former CFO Genzyme, to our Board. His experience advising biotech companies will be invaluable as we further advance the development and realize the commercial potential of our lead clinical asset, GLY-200 for the treatment of #t2d and #obesity.

[Glyscend Inc @glyscend]

Glyscend is proud to announce the issuance of 4 US Patents (US 11,484,548, 11,491,182, 11,491,183, and 11,576,928) establishing further intellectual property coverage for a class of mucus complexing polymers (MCPs) to treat type 2 #diabetes.

[Glyscend Inc @glyscend]

Check out our one-page feature in the December 2022 issue of Nature's Biopharma Dealmakers to learn more about Glyscend’s unique therapeutic approach to treating type 2 #diabetes and #obesity. https://t.co/Qw4fu8zEEy

[Glyscend Inc @glyscend]

Glyscend will be presenting results from our Phase 1 study at ObesityWeek®. Come hear about our oral T2D drug candidate designed to replicate many of the effects of bariatric surgery through pharmacological duodenal exclusion. #OW2022 presentation this Wed, Nov 2nd at 4:45pm PST.

[Glyscend Inc @glyscend]

https://t.co/O9HiADWgTm

[Glyscend Inc @glyscend]

Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment

[Glyscend Inc @glyscend]

A new approach to an old disease! Check out Glyscend's one-page feature in the June'22 issue of Nature's Biopharma Dealmakers.

https://t.co/dfHG7RFFDw

[Glyscend Inc @glyscend]

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
https://t.co/uSeWibkqaE